{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Prostate+Carcinoma", "query": { "condition": "Stage II Prostate Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 868, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Prostate+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-25T16:28:35.899Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01802346", "title": "Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "dietary intervention", "type": "DIETARY_SUPPLEMENT" }, { "name": "nutritional support", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "PROCEDURE", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 130, "start_date": "2013-01-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 3, "location_summary": "Los Angeles, California • Newport Beach, California • Rochester, Minnesota", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802346" }, { "nct_id": "NCT00003622", "title": "Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Ahlgren", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 0, "start_date": "1999-01", "completion_date": "2017-02-22", "has_results": false, "last_update_posted_date": "2017-07-13", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003622" }, { "nct_id": "NCT00006002", "title": "SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "semaxanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2000-06", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 18, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006002" }, { "nct_id": "NCT06067269", "title": "Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Stage II Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 Gozetotide", "type": "OTHER" }, { "name": "Guided Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Multiparametric Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 95, "start_date": "2024-03-28", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067269" }, { "nct_id": "NCT07468903", "title": "Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Adenocarcinoma", "Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8", "Stage II Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "High-Dose Rate Brachytherapy", "type": "RADIATION" }, { "name": "Multiparametric Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "MALE", "summary": "40 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2026-05-11", "completion_date": "2032-05-11", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07468903" }, { "nct_id": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Pilocytic Astrocytoma", "Adult Primary Hepatocellular Carcinoma", "Adult Subependymoma", "Advanced Adult Primary Liver Cancer", "Advanced Malignant Mesothelioma", "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Malignant Mesothelioma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage II Esophageal Cancer", "Stage II Pancreatic Cancer", "Stage III Esophageal Cancer", "Stage III Pancreatic Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030498" }, { "nct_id": "NCT03541928", "title": "Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-risk Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "HSV-Tk", "type": "DRUG" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Brachytherapy, External beam radiotherapy", "type": "RADIATION" }, { "name": "Radical prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2018-08-02", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541928" }, { "nct_id": "NCT01498978", "title": "Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2012-02-06", "completion_date": "2019-01-19", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • Portland, Oregon", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498978" }, { "nct_id": "NCT03473925", "title": "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Non-small Cell Lung Cancer", "Castration Resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer" ], "interventions": [ { "name": "Navarixin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2018-04-10", "completion_date": "2021-05-19", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Baltimore, Maryland + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03473925" }, { "nct_id": "NCT00588640", "title": "Study of D-Methadone in Patients With Chronic Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pain", "Bladder Cancer", "Breast Cancer", "CNS Cancer", "Colon Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Prostate Cancer", "Uterine Cancer", "Head and Neck Cancer", "Eye Cancer", "Otorhinolaryngologic Neoplasms" ], "interventions": [ { "name": "D-methadone", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2004-10", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2016-08-10", "last_synced_at": "2026-07-25T16:28:35.899Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588640" } ] }